Regorafenib (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Regorafenib" in English language version.

refsWebsite

Global rank English rank

9web.archive.org

1^st place

6nih.gov

4^th place

4fda.gov

447^th place

338^th place

3doi.org

2^nd place

2bayer.com

low place

1europa.eu

68^th place

117^th place

1bbc.co.uk

8^th place

10^th place

1nice.org.uk

3,258^th place

2,666^th place

1cancernetwork.com

low place

bayer.com

news.bayer.com

"Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009". Archived from the original on July 11, 2010. Retrieved September 19, 2009.

press.bayer.com

"Phase III Trial of Regorafenib in Metastatic Colorectal Cancer Meets Primary Endpoint of Improving Overall Survival". Archived from the original on January 19, 2012. Retrieved October 26, 2011.

bbc.co.uk

"Cancer fund reprieve for just one drug, Regorafenib". BBC. May 22, 2015. Archived from the original on May 26, 2015. Retrieved June 7, 2015.

cancernetwork.com

"CONSIGN, CONCUR Confirm Efficacy of Regorafenib in mCRC. 2015". Archived from the original on July 15, 2017. Retrieved July 29, 2015.

doi.org

Zhang G, Kodani S, Hammock BD (January 2014). "Stabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and cancer". Progress in Lipid Research. 53: 108–23. doi:10.1016/j.plipres.2013.11.003. PMC 3914417. PMID 24345640.
Hwang SH, Wecksler AT, Zhang G, Morisseau C, Nguyen LV, Fu SH, et al. (July 2013). "Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors". Bioorganic & Medicinal Chemistry Letters. 23 (13): 3732–7. doi:10.1016/j.bmcl.2013.05.011. PMC 3744640. PMID 23726028.
Kim J, Ulu A, Wan D, Yang J, Hammock BD, Weiss RH (May 2016). "Addition of DHA Synergistically Enhances the Efficacy of Regorafenib for Kidney Cancer Therapy". Molecular Cancer Therapeutics. 15 (5): 890–8. doi:10.1158/1535-7163.MCT-15-0847. PMC 4873345. PMID 26921392.

europa.eu

ema.europa.eu

"Stivarga EPAR". European Medicines Agency (EMA). August 26, 2013. Archived from the original on March 6, 2021. Retrieved August 30, 2024.

fda.gov

"FDA approves new treatment for advanced colorectal cancer". September 27, 2012. Archived from the original on January 18, 2017. Retrieved August 30, 2024.
"FDA approves Stivarga for advanced gastrointestinal stromal tumors". February 25, 2013. Archived from the original on January 18, 2017. Retrieved August 30, 2024.

nctr-crs.fda.gov

"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved October 22, 2023.

accessdata.fda.gov

"FDA Prescribing Information" (PDF). September 27, 2012. Archived (PDF) from the original on December 2, 2020. Retrieved September 27, 2012.

nice.org.uk

"Life extending treatment for patients with advanced liver cancer recommended by NICE". November 29, 2018. Archived from the original on November 29, 2018. Retrieved August 30, 2024.

nih.gov

ncbi.nlm.nih.gov

Zhang G, Kodani S, Hammock BD (January 2014). "Stabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and cancer". Progress in Lipid Research. 53: 108–23. doi:10.1016/j.plipres.2013.11.003. PMC 3914417. PMID 24345640.
Hwang SH, Wecksler AT, Zhang G, Morisseau C, Nguyen LV, Fu SH, et al. (July 2013). "Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors". Bioorganic & Medicinal Chemistry Letters. 23 (13): 3732–7. doi:10.1016/j.bmcl.2013.05.011. PMC 3744640. PMID 23726028.
Kim J, Ulu A, Wan D, Yang J, Hammock BD, Weiss RH (May 2016). "Addition of DHA Synergistically Enhances the Efficacy of Regorafenib for Kidney Cancer Therapy". Molecular Cancer Therapeutics. 15 (5): 890–8. doi:10.1158/1535-7163.MCT-15-0847. PMC 4873345. PMID 26921392.

pubmed.ncbi.nlm.nih.gov

Zhang G, Kodani S, Hammock BD (January 2014). "Stabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and cancer". Progress in Lipid Research. 53: 108–23. doi:10.1016/j.plipres.2013.11.003. PMC 3914417. PMID 24345640.
Hwang SH, Wecksler AT, Zhang G, Morisseau C, Nguyen LV, Fu SH, et al. (July 2013). "Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors". Bioorganic & Medicinal Chemistry Letters. 23 (13): 3732–7. doi:10.1016/j.bmcl.2013.05.011. PMC 3744640. PMID 23726028.
Kim J, Ulu A, Wan D, Yang J, Hammock BD, Weiss RH (May 2016). "Addition of DHA Synergistically Enhances the Efficacy of Regorafenib for Kidney Cancer Therapy". Molecular Cancer Therapeutics. 15 (5): 890–8. doi:10.1158/1535-7163.MCT-15-0847. PMC 4873345. PMID 26921392.

web.archive.org

"Stivarga EPAR". European Medicines Agency (EMA). August 26, 2013. Archived from the original on March 6, 2021. Retrieved August 30, 2024.
"Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009". Archived from the original on July 11, 2010. Retrieved September 19, 2009.
"Phase III Trial of Regorafenib in Metastatic Colorectal Cancer Meets Primary Endpoint of Improving Overall Survival". Archived from the original on January 19, 2012. Retrieved October 26, 2011.
"FDA approves new treatment for advanced colorectal cancer". September 27, 2012. Archived from the original on January 18, 2017. Retrieved August 30, 2024.
"Cancer fund reprieve for just one drug, Regorafenib". BBC. May 22, 2015. Archived from the original on May 26, 2015. Retrieved June 7, 2015.
"FDA approves Stivarga for advanced gastrointestinal stromal tumors". February 25, 2013. Archived from the original on January 18, 2017. Retrieved August 30, 2024.
"Life extending treatment for patients with advanced liver cancer recommended by NICE". November 29, 2018. Archived from the original on November 29, 2018. Retrieved August 30, 2024.
"CONSIGN, CONCUR Confirm Efficacy of Regorafenib in mCRC. 2015". Archived from the original on July 15, 2017. Retrieved July 29, 2015.
"FDA Prescribing Information" (PDF). September 27, 2012. Archived (PDF) from the original on December 2, 2020. Retrieved September 27, 2012.